The History of the Myelodysplastic Syndromes

Chapter

Abstract

The concept of the myelodysplastic syndromes (MDS) arose gradually during the twentieth century but depended on a number of seminal earlier discoveries and developments including aniline dye staining of blood cells as introduced by Paul Ehrlich. The MDS have had a multitude of prior names which inhibited comparative research until the publication over the past 30 years of a series of internationally agreed systems of classification which have standardised terminology. Reports of effective treatment have been published only recently but the field holds great promise.

Keywords

Myelodysplastic Syndrome Pernicious Anaemia Refractory Anaemia Classification Classification Megaloblastic Anaemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Neumann E (1869) Über die Bedeutung des Knochenmarkes für die Blutbildung. ein Beitrag zue Entwicklungsgeschichte der Blutkörperchen. Arch Heilkd 10:68–102Google Scholar
  2. 2.
    Tavassoli M (1980) Bone marrow: the seedbed of blood. In: Wintrobe MM (ed) Blood, pure and eloquent. McGraw-Hill, New York, pp 57–79Google Scholar
  3. 3.
    Ehrlich P (1879) Methodologische Beiträge zur Physiologie und Patholgie der verschiedenen Formen der Leukocyten. Z Klin Med 1:553–560Google Scholar
  4. 4.
    Ehrlich P (1877) Beitrag zur Kenntnis der Anilinfärbungen und ihrer Verwendung in der mikroskopischen. Technik Arch Mikr Anat 13:263–277CrossRefGoogle Scholar
  5. 5.
    Wintrobe MM (1980) Blood, pure and eloquent. McGraw-Hill, New YorkGoogle Scholar
  6. 6.
    Matsuo T, Tomonaga M, Bennett JM, Kuriyama K, Imanaka F, Kuramoto A, Kamada N, Ichimaru M, Finch SC, Pisciotta AV et al (1988) Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol 18:91–96PubMedGoogle Scholar
  7. 7.
    Curie E (1937) Madame Curie. Doubleday, Garden CityGoogle Scholar
  8. 8.
    Layton DM, Mufti GJ (1986) Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia. Blut 53:423–436PubMedCrossRefGoogle Scholar
  9. 9.
    von Leube W (1900) Rapid verlaufende schwere Anämie mit gleichzeitiger leukämischer Veränderung des Blutbildes. Klin Wochenschr 37:85–97Google Scholar
  10. 10.
    Luzzatto AM (1907) Sull anemia grave megiloblastica sensa reporto ematologica correspondente (anemia pseudoaplastica). Riv Veneta Med Venezia 47:193Google Scholar
  11. 11.
    Rhoades CP, Barker WH (1938) Refractory anemia: an analysis of one hundred cases. J Am Med Assoc 110:794–796CrossRefGoogle Scholar
  12. 12.
    Bomford RR, Rhodes CP (1941) Refractory anemia. Q J Med 10:175–281Google Scholar
  13. 13.
    Sabine JC (1940) A history of the classification of human blood corpuscles. Bull Hist Med 8:696–720, 785–805Google Scholar
  14. 14.
    Chevallier P, LaMotte M, Umdenstock R (1942) Trois cas d’anémie-leucose benzolique. Le Sang 15:391–405Google Scholar
  15. 15.
    Hamilton-Paterson JL (1949) Preleukemia anemia. Acta Hematol 2:309–316CrossRefGoogle Scholar
  16. 16.
    Block M, Jacobson LO, Bethard WF (1953) Preleukemic acute human leukaemia. J Am Med Assoc 152:1018–1028PubMedCrossRefGoogle Scholar
  17. 17.
    Björkman SE (1956) Chronic refractory anemia with sideroblastic bone marrow; a study of four cases. Blood 11:250–259PubMedGoogle Scholar
  18. 18.
    Rheingold JJ (1974) Acute leukemia. Its smoldering phase, or leukemia never starts on thursday. J Am Med Assoc 230:985–986PubMedGoogle Scholar
  19. 19.
    Rheingold JJ, Kaufman R, Adelson E, Lear A (1963) Smoldering acute leukemia. N Engl J Med 268:812–815PubMedCrossRefGoogle Scholar
  20. 20.
    Rosenthal DS, Moloney WC (1984) Refractory dysmyelopoietic anemia and acute leukemia. Blood 63:314–318PubMedGoogle Scholar
  21. 21.
    Cohen JR, Creger WP, Greenberg PL, Schrier SL (1979) Subacute myeloid leukemia: a clinical review. Am J Med 66:959–966PubMedCrossRefGoogle Scholar
  22. 22.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451–458PubMedCrossRefGoogle Scholar
  23. 23.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMedGoogle Scholar
  24. 24.
    Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131–133PubMedGoogle Scholar
  25. 25.
    Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of the haematopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
  26. 26.
    Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951PubMedCrossRefGoogle Scholar
  27. 27.
    Raskind WH, Tirumali N, Jacobson R, Singer J, Fialkow PJ (1984) Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 63:1318–1323PubMedGoogle Scholar
  28. 28.
    Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (1974) Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251:437–438PubMedCrossRefGoogle Scholar
  29. 29.
    Haase D (2008) Cytogenetic features in myelodysplastic syndromes. Ann Hematol 87:515–526PubMedCrossRefGoogle Scholar
  30. 30.
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMedGoogle Scholar
  31. 31.
    Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59:425–433PubMedCrossRefGoogle Scholar
  32. 32.
    Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74:395–408PubMedGoogle Scholar
  33. 33.
    Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52–59PubMedGoogle Scholar
  34. 34.
    Tallman MS, McGuffin RW, Higano CS, Starkebaum G, Collins SJ, Johnston H, Singer JW, Perry DJ, Kunath A (1987) Bone marrow transplantation in a patient with myelodysplasia associated with diffuse eosinophilic fasciitis. Am J Hematol 24:93–99PubMedCrossRefGoogle Scholar
  35. 35.
    Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1552PubMedCrossRefGoogle Scholar
  36. 36.
    Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T (1991) Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 37:100–104PubMedCrossRefGoogle Scholar
  37. 37.
    List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549–557PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of Clinical Haematology and Medical Oncology and Menzies Research Institute TasmaniaRoyal Hobart HospitalHobartAustralia

Personalised recommendations